Kronos Bio
Research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 57 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | (1904 %) | (328 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (1792 %) | (874 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | - | 1374 % | 494 % |
Source: Company filings or news article
Related Content
Kronos Bio is a clinical-stage biopharmaceutical company focused on discovering and developing novel cancer therapeutics. The company specializes in targeting dysregulated transcription, a process where the genetic information in DNA is copied into RNA, which can lead to cancer. Kronos Bio operates primarily in the oncology market, serving patients with various types of cancer. The business model revolves around a robust pipeline of clinical and preclinical candidates, developed through both internal discovery efforts and strategic asset acquisitions. Revenue is generated through the development and eventual commercialization of these therapeutics, as well as potential partnerships and licensing agreements. The company’s lead product candidate, ENTO, and other investigational drugs like KB-0742, are designed to offer new treatment options for cancer patients. Kronos Bio leverages its translational expertise to drive hypothesis-driven clinical trials aimed at delivering proof of concept for its therapies.
Keywords: cancer therapeutics, dysregulated transcription, oncology, clinical-stage, biopharmaceutical, ENTO, KB-0742, hypothesis-driven, translational expertise, asset acquisition.